Oncology
Despite inquiry, FDA AdCom backs BMS Abecma approval
Despite the recent controversies surrounding chimeric antigen receptor (CAR)-T therapies, a US Food and Drug Administration (FDA) committee voted eight…
Norgine secures Pedmarqsi licence from Fennec in deal worth up to $272m
Fennec Pharmaceuticals has signed an exclusive licence agreement with Norgine to commercialise the former’s hearing loss therapy Pedmarqsi (sodium thiosulphate…
FDA approves BeiGene’s TEVIMBRA for oesophageal cancer
The US Food and Drug Administration (FDA) has approved BeiGene's TEVIMBRA (tislelizumab-jsgr) for the treatment of adults with unresectable or…
Lamassu Bio secures US NIH grant for sarcoma treatment
Lamassu Bio has received a $2.05m grant from the US National Institutes of Health (NIH) and National Cancer Institute (NCI)…
Pearl Bio and Merck partner for discovery of cancer therapies
Synthetic biology company Pearl Bio has signed a licence, partnership and option agreement with Merck for the discovery of biologic…
Terns scores FDA orphan designation for CML therapy
The US Food and Drug Administration (FDA) has granted an orphan drug designation to Terns Pharmaceuticals’s TERN-701 for the treatment…
Merck completes acquisition of Harpoon Therapeutics
Merck & Co. (MSD) has concluded the acquisition of Harpoon Therapeutics to broaden its oncology pipeline. In January 2024, MSD…
BeiGene secures accelerated FDA approval for follicular lymphoma treatment
The US Food and Drug Administration (FDA) has granted accelerated approval to BeiGene’s Brukinsa (zanubrutinib) for patients with advanced forms…
Johnson & Johnson acquires Ambrx Biopharma for $2bn
Johnson & Johnson (J&J) has concluded the acquisition of clinical-stage biopharmaceutical company Ambrx Biopharma in a $2bn transaction. The companies…
FDA approves BMS’ Opdivo for urothelial carcinoma
The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) for the first-line…